These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32216593)

  • 1. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
    Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
    Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
    Shen PC; Chang WC; Lo CH; Yang JF; Lee MS; Dai YH; Lin CS; Fan CY; Huang WY
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):307-318. PubMed ID: 31175903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
    J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.
    Lee S; Jung J; Park JH; Kim SY; Choi J; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Park HH; Kim JH; Yoon SM
    BMC Cancer; 2022 Feb; 22(1):175. PubMed ID: 35172769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.
    Kimura T; Takeda A; Tsurugai Y; Kawano R; Doi Y; Oku Y; Hioki K; Miura H; Nagata Y
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1265-1275. PubMed ID: 32712256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
    Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
    Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
    Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
    Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of radiofrequency ablation compared with transarterial chemoembolization for the treatment of recurrent hepatocellular carcinoma: a comparative survival analysis.
    Koh PS; Chan AC; Cheung TT; Chok KS; Dai WC; Poon RT; Lo CM
    HPB (Oxford); 2016 Jan; 18(1):72-8. PubMed ID: 26776854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC; Chiang CL; Lee AS; Lee VH; Yeung CS; Ho CH; Cheung TT; Ng KK; Chok SH; Chan AC; Dai WC; Wong FC; Luk MY; Leung TW; Lo CM
    Surg Oncol; 2019 Mar; 28():228-235. PubMed ID: 30851906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma.
    Ozyigit G; Cengiz M; Yazici G; Yildiz F; Gurkaynak M; Zorlu F; Yildiz D; Hosal S; Gullu I; Akyol F
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e263-8. PubMed ID: 21514737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
    Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
    Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
    Jang WI; Bae SH; Kim MS; Han CJ; Park SC; Kim SB; Cho EH; Choi CW; Kim KS; Hwang S; Kim JH; Chang AR; Park Y; Kim ES; Kim WC; Jo S; Park HJ
    Cancer; 2020 Jan; 126(2):363-372. PubMed ID: 31747476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
    Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
    J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI; Kim MS; Bae SH; Cho CK; Yoo HJ; Seo YS; Kang JK; Kim SY; Lee DH; Han CJ; Kim J; Park SC; Kim SB; Cho EH; Kim YH
    Radiat Oncol; 2013 Oct; 8():250. PubMed ID: 24160944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study.
    Shiba S; Shibuya K; Katoh H; Kaminuma T; Miyazaki M; Kakizaki S; Shirabe K; Ohno T; Nakano T
    Radiat Oncol; 2019 Aug; 14(1):137. PubMed ID: 31375120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
    Mathew AS; Atenafu EG; Owen D; Maurino C; Brade A; Brierley J; Dinniwell R; Kim J; Cho C; Ringash J; Wong R; Cuneo K; Feng M; Lawrence TS; Dawson LA
    Eur J Cancer; 2020 Jul; 134():41-51. PubMed ID: 32460180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
    Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
    Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients.
    Yamashita H; Onishi H; Matsumoto Y; Murakami N; Matsuo Y; Nomiya T; Nakagawa K;
    Radiat Oncol; 2014 May; 9():112. PubMed ID: 24886477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.